Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Optimizing intracellular antibodies (intrabodies/nanobodies) to treat neurodegenerative disorders

25 Oct 2019

Abstract excerpt

Intrabodies (both single-chain Fv and single-domain VH, VHH, and VL nanobodies) offer unique solutions to some of the challenges of delivery and target engagement posed by immunotherapeutics for the brain and other areas of the nervous system. The specificity, which includes the recognition of post-translational modifications, and capacity for engineering that characterize these antibody fragments can be...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cellular transport and secretion
Share to Genetic Neurodegenerative Diseases
Share to Monoclonal and Polyclonal Antibodies Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31669671
DOI: 10.1016/j.nbd.2019.104619

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Optimizing intracellular antibodies (intrabodies/nanobodies) to treat neurodegenerative disordersPMID 31669671Read ↗

Intrabody applications in neurological disorders: progress and future prospectsSemantic proximity Read ↗

Anti-tau intrabodies: From anti-tau immunoglobulins to the development of functional scFv intrabodiesSemantic proximity Read ↗

Nanobody Therapeutics in Alzheimer’s Disease: From Molecular Mechanisms to Translational ApproachesSemantic proximity Read ↗

Targeting intracellular tau with a gene-encoded single-chain antibody promotes neuronal homeostasis and ameliorates tau pathologySemantic proximity Read ↗

Reliable repurposing of antibody interactome inside the cellSemantic proximity Read ↗

Applying Antibodies Inside Cells: Principles and Recent Advances in Neurobiology, Virology and OncologySemantic proximity Read ↗

Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody.Semantic proximity Read ↗

Bifunctional anti-huntingtin proteasome-directed intrabodies mediate efficient degradation of mutant huntingtin exon 1 protein fragments.Semantic proximity Read ↗

Engineered Nanobodies With Programmable Target Antigen Proteolysis (Ptap) Fusions Regulate Intracellular Alpha-synuclein in Vitro and in VivoSemantic proximity Read ↗

Advances in nanobody multimerization and multispecificity: from in vivo assembly to in vitro productionSemantic proximity Read ↗

Human single-chain Fv intrabodies counteract <i>in situ</i> huntingtin aggregation in cellular models of Huntington's diseaseSemantic proximity Read ↗

Targeting tauopathy with engineered tau-degrading intrabodies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.